A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer
Status:
Completed
Trial end date:
2021-05-27
Target enrollment:
Participant gender:
Summary
This is a Phase III, randomized, double blind, multicenter, active comparator, parallel two
arm study to compare the efficacy, and to evaluate the safety, and immunogenicity of BAT1706
to EU Avastin® in patients with previously untreated advanced non-squamous non-small cell
lung cancer (nsNSCLC) to demonstrate clinical equivalence of BAT1706 and EU Avastin®.